{"url_path":"/sec/hcwb/8-k/2026-06-30/item-3-01","section_key":"item-3-01","section_title":"Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1828673/0001493152-26-031204-index.html","accession_number":"0001493152-26-031204","cik":"0001828673","ticker":"HCWB","issuer_name":"HCW Biologics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1828673/0001493152-26-031204-index.html","primary_entity_key":"0001828673","primary_entity_name":"HCW Biologics Inc."},"word_count":304,"has_tables":true,"body_markdown":"**Item\n3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**\n\n \n\nOn\nJune 29, 2026, HCW Biologics Inc. (the “Company”) received written notice form the Listing Qualifications Staff (the “Staff”)\nof the Nasdaq Capital Market Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”)\nfound that the Company regained compliance with Listing Rule 5550(a)(2), the “Bid Price Rule,” per the terms set forth in\nthe Panel’s decision letter dated May 29, 2026, as amended.\n\n \n\nAs\nindicated in the Panel’s decision letter, as amended, if the Company satisfies the remaining terms of the decision through September\n22, 2026, the Panel also intends to impose a Discretionary Panel Monitor on the Company pursuant to Listing Rule 5815(d)(4)(A) for a\none-year period from that date.\n\n \n\nIn\napplication of Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor until June 17, 2027. If, within that\none-year monitoring period, Staff finds the Company again out of compliance with the Bid Price Rule, which was the subject of the exception,\nthen notwithstanding Rule 5810(c)(2) the Company will not be permitted to provide the Staff with a plan of compliance with respect to\nthat deficiency and Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency,\nnor will the company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, Staff will issue a Delist\nDetermination Letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings\nPanel if the initial Panel is unavailable. The Company will have the opportunity to respond/present to the Hearings Panel as provided\nby Listing Rule 5815(d)(4)(C). The Company’s securities may be at that time delisted from Nasdaq."}